Ann: Capital Raising Presentation, page-75

Very honest appraisal JB. Also leg/foot ulcer studies overseas using stem cells in diabetic patients progressing. CYP needs to up its game. But before all the peanut crowd chime in, it is cheap as chips down here.

I saw one of my US stem cells Gamida up 44% overnight on an allogenic stem cell approval. Fate +10%, BioCardia +10%.

CYP is on its lows with the rest of the sector. Some getting a nice bounce and the regulatory environment for stem cell trials, ISPC's or otherwise has dramatically improved in the last year. I feel sorry for (some) long term holders, but there is value down here in the low share price in response to trial tardiness and lack of commercial progress from Ross and co.

Regulatory advancements and even approvals in the sector coming in daily overseas.